Search

YoungEHA Committee

Current committee members
Mandy Lauw, The Netherlands (Chair)
Anna Kabanova, Italy (Vice Chair)
Elizabeth Macintyre, France (EHA Past President)
Regular members
Anna Avagyan, Armenia
Nuno Borges, United Kingdom
Katherine Bridge, United Kingdom
Lorenzo Brunetti, Italy
Eleni Gavriilaki, Greece
William Grey, United Kingdom
Ruxandra Irimia, Romania
Rafal Machowicz, Poland
Anna Maiques Diaz, Spain
Ana Filipa…

SPC Advisory Board, EHA Congress 2024

Current committee members
Valentine Brousse, France
Veronika Buxhofer-Ausch, Austria
Ana Cvejic, Denmark
Mattia D'Agostino, Italy
Thierry Facon, France
Krystof Giannopoulos, Poland
Julia Hauer, Germany
Dan Hodson, United Kingdom
Sören Lehmann, Sweden
Georg Lenz, Germany
Sirpa Leppä, Finland
Karina Meijer, The Netherlands
Emma Morris, United Kingdom
Cristina Papayannidis, Italy
France Pirenne, France
Delphine Rea, France
Sonata Šaulytė Trakymienė, Lithuania
Barbara…

General Information

June 1, 2024
EHA2024 Congress platform opens

June 13-16, 2024
EHA2024 Madrid, Spain - In-person and live stream

Location
IFEMA MADRID RECINTO FERIAL (Fairgrounds), Madrid, Spain

August 15, 2024
EHA2024 Congress platform closes

Scientific Program Committee (SPC) Chair
Prof Brian Huntly

Official Language
English

EHA Congress Secretariat
INTERPLAN Congress, Meeting & Event Management…

European Affairs Committee

Current committee members
Elizabeth Macintyre, France (Chair (EHA Past President))
Antonio Almeida, Portugal (EHA President)
Natacha Bolaños, Spain (EHA PO Workgroup)
Lorenzo Brunetti, Italy (YoungEHA)
Isabelle Durand-Zaleski, France (Advisory member)
Frank Leebeek, The Netherlands (Advisory member (Councilor))
Kate Morgan, United Kingdom (EHA PO Workgroup)
Kostas Stamatopoulos, Greece (EHA…

A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia

Jun 12 2015 Posted in Press releases

Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.